Short-term Investments

9 Months Ended

Oct. 31, 2016

Investments Debt And Equity Securities [Abstract]

Short-term Investments

3. Short-term Investments

Short-term investments consisted of the following (in thousands):

	As of October 31, 2016
	Amortized Cost		Unrealized Losses			Unrealized Gains		Fair Value
Corporate debt securities	$	11,697	$	(5	)	$	1	$	11,693
Commercial paper		9,376		—			—		9,376
U.S. agency securities		6,567		—			7		6,574
U.S. government securities		18,044		—			15		18,059
Asset-backed securities		1,352		—			—		1,352
Total short-term investments	$	47,036	$	(5	)	$	23	$	47,054
	As of January 31, 2016
	Amortized Cost		Unrealized Losses			Unrealized Gains		Fair Value
Corporate debt securities	$	7,851	$	(6	)	$	—	$	7,845
Commercial paper		4,985		—			1		4,986
U.S. agency securities		7,661		—			5		7,666
U.S. government securities		7,477		—			17		7,494
Total short-term investments	$	27,974	$	(6	)	$	23	$	27,991

The gross realized gains and losses related to the Company’s short-term investments were not material for the three and nine months ended October 31, 2016. The Company did not have any gross realized gains or gross realized losses for the three and nine months ended October 31, 2015.

The cost basis and fair value of the short-term investments by contractual maturity were as follows (in thousands):

	As of October 31, 2016				As of January 31, 2016
	Amortized Value		Fair Value		Amortized Value		Fair Value
One year or less	$	41,485	$	41,495	$	19,143	$	19,145
Over one year and less than two years		5,551		5,559		8,831		8,846
Total	$	47,036	$	47,054	$	27,974	$	27,991

Investments in an unrealized loss position consisted of the following (in thousands):

	As of October 31, 2016					As of January 31, 2016
	Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
Corporate debt securities	$	11,693	$	(5	)	$	7,845	$	(6	)

The Company reviews the individual securities in its portfolio to determine whether a decline in a security’s fair value below the amortized cost basis is other-than-temporary. The Company determined that as of October 31, 2016 and January 31, 2016, there were no investments in its portfolio that were other-than-temporarily impaired. The Company does not intend to sell any of these investments, and it is not more likely than not that the Company would be required to sell these investments before recovery of their amortized cost basis, which may be at maturity.